di-p-tolyl phenoxycarbonylphosphonate | 74270-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: di-p-tolyl phenoxycarbonylphosphonate
• 英文别名: Phosphinecarboxylic acid, bis(4-methylphenoxy)-, phenyl ester, oxide；phenyl bis(4-methylphenoxy)phosphorylformate
• CAS: 74270-17-0
• 化学式: C₂₁H₁₉O₅P
• 分子量: 382.353
• InChiKey: IORAAQDUDVGXSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  di-p-tolyl phenoxycarbonylphosphonate 以83%的产率得到
  参考文献：
  名称：

  NOREN, J. O.;HELGSTRAND, E.;JOHANSSON, N. G.;MISIORNY, A.;STENING, G., J. MED. CHEM., 1983, 26, N 2, 264-270

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl bis(4-methylphenyl)phosphite 、 氯甲酸苯酯 生成 di-p-tolyl phenoxycarbonylphosphonate
  参考文献：
  名称：

  Phosphonoformic acid esters

  摘要：

  式##STR1##的化合物，其中R.sub.1、R.sub.2和R.sub.3相同或不同，且每个均选自由氢和苯基组成的群，该群的式为##STR2##，其中R.sub.4和R.sub.5相同或不同，每个均选自由氢、卤素、具有1、2或3个碳原子的烷基、具有1、2或3个碳原子的烷氧基、具有2-7个碳原子的烷氧羰基；和具有2-7个碳原子的烷基羰基；或者R.sub.4和R.sub.5一起形成直链饱和的具有3或4个碳原子的烷基链，并与相邻位置即苯环中的2,3-或3,4-相连；前提是当R.sub.3为H时，R.sub.1和R.sub.2中的一个是式II的苯基；以及其生理上可接受的盐和光学异构体；制备这些化合物的方法，含有它们的药物组合物，以及它们的药用。

  公开号：

  US04372894A1

文献信息

• Aromatic derivatives of phosphonoformic acid, processes for their preparation, pharmaceutical compositions containing them and their use for combating virus infections
  申请人：Astra Läkemedel Aktiebolag

  公开号：EP0003275A1

  公开（公告）日：1979-08-08

  A compound of the formula wherein R,, R2 and R3 are the same or different, and each is selected from the group consisting of hydrogen and phenyl groups of the formula wherein R4 and R5 are the same or different and each is. selected from the group consisting of hydrogen, halogen, alkyl having 1; 2, or 3 carbon atoms, alkoxy having 7,2. or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms; and alkylcarbonyl groups having 2-7 carbon atoms; or R4 and R5 together form a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; provided that one of R1 and R2 is a phenyl group of the formula II when R3 is H; and physiologically acceptable salts and optical isomers thereof; methods for preparation of the compounds, pharmaceutical compositions containing them, and their medicinal use.

  式中的化合物 其中 R、R2 和 R3 相同或不同，且各自选自由氢和式中的苯基组成的组 其中 R4 和 R5 相同或不同，且各自选自由氢、卤素、具有 1；2 或 3 个碳原子的烷基、具有 7、2. 或 3 个碳原子的烷氧基、具有 2-7 个碳原子的烷氧羰基；以及具有 2-7 个碳原子的烷基羰基组成的组；或 R4 和 R5 共同形成具有 3 或 4 个碳原子的直饱和亚烷基链，并与相邻位置结合，即即苯基环中的2,3-或3,4-；条件是当R3为H时，R1和R2中的一个是式II的苯基；以及它们的生理上可接受的盐和光学异构体；化合物的制备方法、含有它们的药物组合物及其药用用途。
• Nonaqueous electrolyte solution, electricity storage device using same, and phosphonoformic acid compound used in same
  申请人：UBE INDUSTRIES, LTD.

  公开号：US10374256B2

  公开（公告）日：2019-08-06

  The present invention provides a nonaqueous electrolytic solution capable of suppressing worsening of heat stability of a negative electrode and improving safety of an energy storage device while maintaining high-load charging and discharging cycle properties at a high temperature, an energy storage device using the same, and a phosphonoformic acid compound to be used for the same. The nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent contains 0.001 to 5% by mass of at least one selected from a phosphonoformic acid compound having at least one carbon-carbon unsaturated bond, which is represented by the following general formula (I), and a phosphonoformic acid compound having a carbon-carbon unsaturated bond or two phosphonocarbonyl groups, which is represented by the following general formula (II). In the formula (I), each of R1 to R3 is an aliphatic organic group, provided that at least one of R1 to R3 represents a carbon-carbon unsaturated bond-containing aliphatic organic group. In the formula (II), each of R4 and R5 represents an alkyl group, a cycloalkyl group, or an aryl group, and R4 and R5 may be bonded to each other to form a ring structure. m represents 1 or 2; when m is 1, then R6 represents an aryl group; when m is 2, then R6 represents an alkylene group, an alkenylene group, or an alkynylene group; and a part of hydrogen atoms of R4 to R6 may be substituted with a halogen atom.

  本发明提供了一种在高温下保持高负荷充放电循环特性的同时，能够抑制负极热稳定性恶化并提高储能装置安全性的非水性电解溶液、使用该溶液的储能装置以及用于该溶液的膦甲酸化合物。具有溶解在非水溶剂中的电解质盐的非水电解溶液含有 0.001%至 5%（以质量计）的至少一种选自具有至少一个碳碳不饱和键的膦甲酸化合物（由以下通式 (I) 表示）和具有一个碳碳不饱和键或两个膦酰基的膦甲酸化合物（由以下通式 (II) 表示）。 在式 (I) 中，R1 至 R3 中的每一个都是脂肪族有机基团，条件是 R1 至 R3 中至少有一个代表含碳碳不饱和键的脂肪族有机基团。 在式 (II) 中，R4 和 R5 各自代表烷基、环烷基或芳基，且 R4 和 R5 可相互键合以形成环状结构。m 代表 1 或 2；当 m 为 1 时，则 R6 代表芳基；当 m 为 2 时，则 R6 代表亚烷基、亚烯基或亚炔基；且 R4 至 R6 的部分氢原子可被卤原子取代。
• Synthesis of esters of phosphonoformic acid and their antiherpes activity
  作者：Jan O. Noren、Erik Helgstrand、Nils G. Johansson、Alfons Misiorny、Goeran Stening

  DOI：10.1021/jm00356a028

  日期：1983.2

  Aliphatic and aromatic mono-, di-, and triesters of phosphonoformic acid (foscarnet) were synthesized. The triesters were prepared by the Michaelis-Arbuzov reaction and were hydrolyzed to di- and monoesters. The compounds were tested for antiviral activity on isolated herpes simplex virus type 1 (HSV-1) DNA polymerase, in a HSV-1 plaque reduction assay, and on a cutaneous HSV-1 infection in guinea pigs. None of the esters inhibited the activity of isolated HSV-1 polymerases. Monoesters with a free carboxylic group and diesters with an aromatic carboxylic ester function were active against the cutaneous herpes infection. Mono- and diesters with an aromatic phosphonic ester group also showed activity in the plaque-reduction assay. However, mono- and diesters with an aromatic phosphonic ester group also showed activity in the plaque-reduction assay. However, mono- and diesters with aliphatic carboxylic ester groups were inactive in all test systems. The results show that all three acidic groups of phosphonoformic acid must be free in order to get antiviral activity at the enzyme level. However, certain esters of this acid may be biotransformed to the acid itself to give antiherpes activity.
• NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME
  申请人：UBE INDUSTRIES, LTD

  公开号：US20160315351A1

  公开（公告）日：2016-10-27

  The present invention provides a nonaqueous electrolytic solution capable of suppressing worsening of heat stability of a negative electrode and improving safety of an energy storage device while maintaining high-load charging and discharging cycle properties at a high temperature, an energy storage device using the same, and a phosphonoformic acid compound to be used for the same. The nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent contains 0.001 to 5% by mass of at least one selected from a phosphonoformic acid compound having at least one carbon-carbon unsaturated bond, which is represented by the following general formula (I), and a phosphonoformic acid compound having a carbon-carbon unsaturated bond or two phosphonocarbonyl groups, which is represented by the following general formula (II). In the formula (I), each of R 1 to R 3 is an aliphatic organic group, provided that at least one of R 1 to R 3 represents a carbon-carbon unsaturated bond-containing aliphatic organic group. In the formula (II), each of R 4 and R 5 represents an alkyl group, a cycloalkyl group, or an aryl group, and R 4 and R 5 may be bonded to each other to form a ring structure. m represents 1 or 2; when m is 1, then R 6 represents an aryl group; when m is 2, then R 6 represents an alkylene group, an alkenylene group, or an alkynylene group; and a part of hydrogen atoms of R 4 to R 6 may be substituted with a halogen atom.
• US4372894A
  申请人：——

  公开号：US4372894A

  公开（公告）日：1983-02-08